JP2008533154A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008533154A5 JP2008533154A5 JP2008501960A JP2008501960A JP2008533154A5 JP 2008533154 A5 JP2008533154 A5 JP 2008533154A5 JP 2008501960 A JP2008501960 A JP 2008501960A JP 2008501960 A JP2008501960 A JP 2008501960A JP 2008533154 A5 JP2008533154 A5 JP 2008533154A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- independently
- halo
- compound according
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 cycloheteroalkyl Chemical group 0.000 claims 48
- 150000001875 compounds Chemical class 0.000 claims 47
- 125000005843 halogen group Chemical group 0.000 claims 42
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 37
- 125000003118 aryl group Chemical group 0.000 claims 24
- 229910052739 hydrogen Inorganic materials 0.000 claims 20
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 12
- 125000001072 heteroaryl group Chemical group 0.000 claims 12
- 229910052799 carbon Inorganic materials 0.000 claims 11
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 9
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 239000012453 solvate Substances 0.000 claims 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims 8
- 125000004404 heteroalkyl group Chemical group 0.000 claims 8
- 229910052757 nitrogen Inorganic materials 0.000 claims 8
- 208000002193 Pain Diseases 0.000 claims 7
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 239000000651 prodrug Substances 0.000 claims 6
- 229940002612 prodrug Drugs 0.000 claims 6
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims 6
- 150000003457 sulfones Chemical class 0.000 claims 6
- 150000003462 sulfoxides Chemical class 0.000 claims 6
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 5
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 5
- 150000001540 azides Chemical class 0.000 claims 5
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 claims 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 5
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 5
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000004548 quinolin-3-yl group Chemical group N1=CC(=CC2=CC=CC=C12)* 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 claims 2
- 201000006474 Brain Ischemia Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 102000004310 Ion Channels Human genes 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims 2
- 206010047700 Vomiting Diseases 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims 2
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 230000007823 neuropathy Effects 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- 230000008673 vomiting Effects 0.000 claims 2
- XZIRSZNKYZLIJB-UHFFFAOYSA-N 2-methyl-n-(5,6,7,8-tetrahydronaphthalen-1-yl)-4-[2-(trifluoromethyl)cyclopropyl]benzamide Chemical compound C=1C=C(C(=O)NC=2C=3CCCCC=3C=CC=2)C(C)=CC=1C1CC1C(F)(F)F XZIRSZNKYZLIJB-UHFFFAOYSA-N 0.000 claims 1
- VHOKNIKXNQQQDL-UHFFFAOYSA-N 4-(2,2-dichlorocyclopropyl)-n-(3-methoxyphenyl)benzamide Chemical compound COC1=CC=CC(NC(=O)C=2C=CC(=CC=2)C2C(C2)(Cl)Cl)=C1 VHOKNIKXNQQQDL-UHFFFAOYSA-N 0.000 claims 1
- DJNGXGAVGQPENZ-UHFFFAOYSA-N 4-cyclopropyl-n-(3-methoxyphenyl)-2-methylbenzamide Chemical compound COC1=CC=CC(NC(=O)C=2C(=CC(=CC=2)C2CC2)C)=C1 DJNGXGAVGQPENZ-UHFFFAOYSA-N 0.000 claims 1
- 208000008035 Back Pain Diseases 0.000 claims 1
- 125000006414 CCl Chemical group ClC* 0.000 claims 1
- 206010058019 Cancer Pain Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 206010011224 Cough Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000019505 Deglutition disease Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010021639 Incontinence Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000028389 Nerve injury Diseases 0.000 claims 1
- 206010029240 Neuritis Diseases 0.000 claims 1
- 208000001294 Nociceptive Pain Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000031481 Pathologic Constriction Diseases 0.000 claims 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims 1
- 206010038419 Renal colic Diseases 0.000 claims 1
- 208000025747 Rheumatic disease Diseases 0.000 claims 1
- 208000008765 Sciatica Diseases 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 208000028938 Urination disease Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 125000004442 acylamino group Chemical group 0.000 claims 1
- 125000001931 aliphatic group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000004947 alkyl aryl amino group Chemical group 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 claims 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000003295 carpal tunnel syndrome Diseases 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 201000003146 cystitis Diseases 0.000 claims 1
- 125000004663 dialkyl amino group Chemical group 0.000 claims 1
- 230000001079 digestive effect Effects 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- FGUCROUSKZKLPT-UHFFFAOYSA-N n-(3-methoxyphenyl)-2-methyl-4-[2-(trifluoromethyl)cyclopropyl]benzamide Chemical compound COC1=CC=CC(NC(=O)C=2C(=CC(=CC=2)C2C(C2)C(F)(F)F)C)=C1 FGUCROUSKZKLPT-UHFFFAOYSA-N 0.000 claims 1
- SGOHJBHPFBGUCQ-UHFFFAOYSA-N n-(4-tert-butylphenyl)-2-methyl-4-[2-(trifluoromethyl)cyclopropyl]benzamide Chemical compound CC1=CC(C2C(C2)C(F)(F)F)=CC=C1C(=O)NC1=CC=C(C(C)(C)C)C=C1 SGOHJBHPFBGUCQ-UHFFFAOYSA-N 0.000 claims 1
- IYHIPXIQASCSTM-UHFFFAOYSA-N n-(4-tert-butylphenyl)-4-cyclopropyl-2-methylbenzamide Chemical compound CC1=CC(C2CC2)=CC=C1C(=O)NC1=CC=C(C(C)(C)C)C=C1 IYHIPXIQASCSTM-UHFFFAOYSA-N 0.000 claims 1
- CNYOPDRUYNSZMO-UHFFFAOYSA-N n-(6-methoxypyridin-3-yl)-2-methyl-4-[2-(trifluoromethyl)cyclopropyl]benzamide Chemical compound C1=NC(OC)=CC=C1NC(=O)C1=CC=C(C2C(C2)C(F)(F)F)C=C1C CNYOPDRUYNSZMO-UHFFFAOYSA-N 0.000 claims 1
- 230000008764 nerve damage Effects 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 230000003349 osteoarthritic effect Effects 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 230000035479 physiological effects, processes and functions Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 230000000552 rheumatic effect Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000036262 stenosis Effects 0.000 claims 1
- 208000037804 stenosis Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 208000004371 toothache Diseases 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
- 208000026533 urinary bladder disease Diseases 0.000 claims 1
- 208000009935 visceral pain Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66153105P | 2005-03-14 | 2005-03-14 | |
| PCT/US2006/009112 WO2006099410A2 (en) | 2005-03-14 | 2006-03-14 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008533154A JP2008533154A (ja) | 2008-08-21 |
| JP2008533154A5 true JP2008533154A5 (enExample) | 2009-04-16 |
Family
ID=36992376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008501960A Pending JP2008533154A (ja) | 2005-03-14 | 2006-03-14 | イオンチャネルリガンドとしてのアミド誘導体および薬学的組成物およびそれらを使用する方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US7312233B2 (enExample) |
| EP (1) | EP1863757A4 (enExample) |
| JP (1) | JP2008533154A (enExample) |
| CA (1) | CA2601468A1 (enExample) |
| WO (1) | WO2006099410A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009114143A1 (en) * | 2008-03-12 | 2009-09-17 | Brown University | Treatment and prophylaxis of epilepsy and febrile seizures |
| WO2009132050A2 (en) | 2008-04-21 | 2009-10-29 | Otonomy, Inc. | Auris formulations for treating otic diseases and conditions |
| US11969501B2 (en) | 2008-04-21 | 2024-04-30 | Dompé Farmaceutici S.P.A. | Auris formulations for treating otic diseases and conditions |
| SG157299A1 (en) | 2008-05-09 | 2009-12-29 | Agency Science Tech & Res | Diagnosis and treatment of kawasaki disease |
| WO2010011605A2 (en) | 2008-07-21 | 2010-01-28 | Otonomy, Inc. | Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders |
| EP3478269A4 (en) | 2016-06-29 | 2020-04-08 | Otonomy, Inc. | OTIC FORMULATIONS BASED ON TRIGLYCERIDES AND THEIR USES |
| CN111196819B (zh) * | 2018-11-16 | 2023-03-28 | 中国科学院上海药物研究所 | 一类d-a-d型苯并吡嗪类化合物及制备方法和应用 |
| WO2023054626A1 (ja) * | 2021-09-30 | 2023-04-06 | 住友ファーマ株式会社 | シクロプロパンアミド誘導体 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9405347D0 (en) * | 1994-03-18 | 1994-05-04 | Agrevo Uk Ltd | Fungicides |
| FR2729945B1 (fr) * | 1995-01-26 | 1997-04-25 | Hoechst Schering Agrevo Sa | Nouveaux amides aromatiques, leur procede de preparation, les compostions les contenant et leur utilisation comme pesticides |
| US6632815B2 (en) * | 1999-09-17 | 2003-10-14 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| JP2003520854A (ja) * | 2000-01-27 | 2003-07-08 | サイトビア インコーポレイテッド | カスパーゼのアクチベーターおよびアポトーシスのインデューサーとしての置換ニコチンアミドおよび類似物およびそれらの使用 |
| CN1289072C (zh) * | 2000-12-22 | 2006-12-13 | 石原产业株式会社 | 苯胺衍生物或其盐以及含有它们的细胞因子产生抑制剂 |
| US20060100245A1 (en) * | 2002-12-19 | 2006-05-11 | Neurogen Corporation | Substituted biphenyl-4-carboxylic acid arylamide analogues |
| TW200505450A (en) * | 2003-02-03 | 2005-02-16 | Janssen Pharmaceutica Nv | Quinoline-derived amide modulators of vanilloid VR1 receptor |
| WO2005046683A1 (en) * | 2003-10-07 | 2005-05-26 | Renovis, Inc. | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same |
-
2006
- 2006-03-14 US US11/375,692 patent/US7312233B2/en not_active Expired - Fee Related
- 2006-03-14 EP EP06738196A patent/EP1863757A4/en not_active Withdrawn
- 2006-03-14 WO PCT/US2006/009112 patent/WO2006099410A2/en not_active Ceased
- 2006-03-14 CA CA002601468A patent/CA2601468A1/en not_active Abandoned
- 2006-03-14 JP JP2008501960A patent/JP2008533154A/ja active Pending
-
2007
- 2007-08-23 US US11/895,293 patent/US20080096919A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8685992B2 (en) | Histone deacetylase inhibitors based simultaneously on trisubstituted 1H-pyrroles and aromatic and heteroaromatic spacers | |
| JP2014525425A5 (enExample) | ||
| US9034886B2 (en) | 4-aminoquinazoline derivatives and uses thereof | |
| JP2010523722A5 (enExample) | ||
| JP2012502986A5 (enExample) | ||
| JP2012515724A5 (enExample) | ||
| JP2012509352A5 (enExample) | ||
| RU2008100606A (ru) | Ингибиторы сфингозинкиназы | |
| JP2016506963A5 (enExample) | ||
| JP2016503786A5 (enExample) | ||
| JP2022548250A5 (enExample) | ||
| JP2008534511A5 (enExample) | ||
| CA2601508A1 (en) | Cyclopropanecarboxamide derivatives | |
| JP2009536918A5 (enExample) | ||
| JP2013526494A5 (enExample) | ||
| US20190367465A1 (en) | Heterocyclic urea compound, and drug composition and application thereof | |
| JP2011508784A5 (enExample) | ||
| JP2010510202A5 (enExample) | ||
| CA2600409A1 (en) | Substituted n-sulfonylaminophenylethyl-2-phenoxy acetamide compounds | |
| JP2008508247A5 (enExample) | ||
| JP2019532054A5 (enExample) | ||
| CA2610354A1 (en) | Substituted aryloxy-n-bicyclomethyl acetamide compounds as vr1 antagonists | |
| AU2018216954A1 (en) | Piperazine derivatives for influenza virus inhibition | |
| WO2010076034A1 (en) | Toluidine sulfonamides and their use as-inhibitors | |
| JP2015528488A (ja) | 脾臓チロシンキナーゼｉ（ｓｙｋ）阻害剤としての２−（２−アミノシクロヘキシル）アミノピリミジン−５−カルボキサミド類 |